Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
Johnson and Johnson
Express Scripts
AstraZeneca

Last Updated: August 19, 2022

Investigational Drug Information for FG-4592


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug FG-4592?

FG-4592 is an investigational drug.

There have been 28 clinical trials for FG-4592. The most recent clinical trial was a Phase 3 trial, which was initiated on October 20th 2022.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Europe B.V., and AstraZeneca.

There are forty-four US patents protecting this investigational drug and three hundred and eighty-seven international patents.

Recent Clinical Trials for FG-4592
TitleSponsorPhase
Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsSecond Xiangya Hospital of Central South UniversityPhase 4
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid MalignanciesFibroGenPhase 3
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDAstraZenecaPhase 3

See all FG-4592 clinical trials

Clinical Trial Summary for FG-4592

Top disease conditions for FG-4592
Top clinical trial sponsors for FG-4592

See all FG-4592 clinical trials

US Patents for FG-4592

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
FG-4592 See Plans and Pricing Nitrogen-containing heteroaryl compounds and methods of use thereof FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
FG-4592 See Plans and Pricing Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
FG-4592 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
FG-4592 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
FG-4592 See Plans and Pricing Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) See Plans and Pricing
FG-4592 See Plans and Pricing Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for FG-4592

Drugname Country Document Number Estimated Expiration Related US Patent
FG-4592 Austria AT496033 2023-06-06 See Plans and Pricing
FG-4592 Australia AU2004245552 2023-06-06 See Plans and Pricing
FG-4592 Brazil BRPI0411055 2023-06-06 See Plans and Pricing
FG-4592 Canada CA2528232 2023-06-06 See Plans and Pricing
FG-4592 China CN102718708 2023-06-06 See Plans and Pricing
FG-4592 China CN102977015 2023-06-06 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
Johnson and Johnson
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.